ArticleNPJ vaccines2025
Level of antibody to hepatitis B surface antigen declined below 10 mIU/ml is still protective.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Whether declined level <10 mIU/ml of antibody to hepatitis B surface antigen (anti-HBs) is still immune to hepatitis B virus (HBV) is controversial. We longitudinally investigated hepatitis B markers in 395 vaccinated children of HBV-infected mothers at a 5.4-years interval. At baseline, they were at average age of 3.2 ± 1.8 years (0.6-12), and 106 (26.8%) children had anti-HBs <10 mIU/ml and 289 (73.2%) others had anti-HBs ≥10 mIU/ml. Of them, 84 (21.3%) were boosted with hepatitis B vaccine and 311 (78.7%) were not boosted. When they were at the age of 8.6 ± 1.9 years (6-18), 166 (42.1%) had anti-HBs <10 mIU/ml and 229 (57.9%) had anti-HBs ≥10 mIU/ml, and none was infected with HBV, including 62 unboosted children with anti-HBs <10 mIU/ml at baseline. Of 311 unboosted participants, 48 (15.4%) had increased anti-HBs levels in the absence of antibody to hepatitis B core antigen, suggesting natural booster immunization. Considering the close contact of children to their HBV-infected mothers, our study showed that successfully vaccinated children are still immune to HBV, even after the anti-HBs levels dropped to <10 mIU/ml. Therefore, anti-HBs levels <10 mIU/ml should not be an indication for booster hepatitis B vaccination.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.